Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 4/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.68 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.68 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.68 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.68 |
| ▸ | ACHE | P22303 | 1/20 | 0.68 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.68 |
| ▸ | DRD3 | P35462 | 1/20 | 0.68 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2778088 | 1.00 | HIF1A (0.68) | HIF1ACYP3A4ALOX15ALDH1A1PTGS1 | |
| SCHEMBL29588566 | 1.00 | HIF1A (0.68) | HIF1ACYP3A4ALOX15ALDH1A1PTGS1 | |
| Hydrochloric Acid SCHEMBL7613467 | 0.98 | HIF1A (0.66) | HIF1ACYP3A4ALOX15ALDH1A1PTGS1 | |
| Hydrochloric Acid SCHEMBL7613475 | 0.98 | HIF1A (0.66) | HIF1ACYP3A4ALOX15ALDH1A1PTGS1 | |
| Hydrochloric Acid SCHEMBL7613469 | 0.98 | HIF1A (0.66) | HIF1ACYP3A4ALOX15ALDH1A1PTGS1 | |
| SCHEMBL2778114 | 0.91 | HIF1A (0.65) | HIF1ACYP3A4ALOX15ALDH1A1PTGS1 | |
| Hydrochloric Acid SCHEMBL6770868 | 0.90 | HIF1A (0.63) | HIF1ACYP3A4ALOX15ALDH1A1PTGS1 | |
| Hydrochloric Acid SCHEMBL7717463 | 0.90 | HIF1A (0.63) | HIF1ACYP3A4ALOX15ALDH1A1PTGS1 | |
| Hydrochloric Acid SCHEMBL6776947 | 0.90 | HIF1A (0.63) | HIF1ACYP3A4ALOX15ALDH1A1PTGS1 | |
| SCHEMBL18645038 | 0.87 | HIF1A (0.73) | HIF1ACYP3A4ALOX15ALDH1A1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230391828-A1 | REGULATORS OF CELL DIVISION | TECHNISCHE UNIVERSITAT DRESDEN (DE) | 2023-12-07 | — | — | US | disclosed |
| EP-3981784-A1 | REGULATORS OF CELL DIVISION | Technische Universität Dresden (DE) | 2022-04-13 | — | — | EP | disclosed |
| EP-2248901-A1 | Streptogramines and method for preparing same by mutasynthesis | Aventis Pharma S.A. (FR) | 2010-11-10 | — | — | EP | disclosed |
| EP-0770132-B1 | NEW STREPTOGRAMINES | AVENTIS PHARMA SA (FR) | 2010-09-08 | — | — | EP | disclosed |
| US-6833382-B2 | By muta-synthesis using a mutated micro-organism to influence the biosynthesis of at least one of the precursors of group B streptogramines; mutant strain employed is preferably derived from the strain S. pristinaespiralis SP92 | AVENTIS PHARMA S.A. (FR) | 2004-12-21 | — | — | US | disclosed |
| US-20020142947-A1 | STREPTOGRAMINS AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS | AVENTIS PHARMA, S.A. | 2002-10-03 | — | — | US | disclosed |
| US-6384014-B1 | ANTIBIOTICS AS BACTERICIDES | AVENTIS PHARMA S.A. (FR) | 2002-05-07 | — | — | US | disclosed |
| US-6352839-B1 | PREPARING VIRGINIAMYCINS FROM AN ENGINEERED MICROORGANISMS, HAVING THE ABILITY TO PREVENT BIOSYNTHESIS OF THE PRECURSOR ANTIBIOTIC; THE MICROORGANISM IS CULTURED IN THE PRESENCE OF A SECOND PRECURSOR AND THE STREPTOGRAMIN ANALOG IS RECOVERED | AVENTIS PHARMA S.A. (FR) | 2002-03-05 | — | — | US | disclosed |
| EP-0773956-B1 | PURIFIED FORM OF STREPTOGRAMINES, PREPARATION OF SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2001-07-04 | — | — | EP | disclosed |
| EP-0773956-A1 | PURIFIED FORM OF STREPTOGRAMINES, PREPARATION OF SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Aventis Pharma S.A. (FR) | 1997-05-21 | — | — | EP | disclosed |
| EP-0770132-A1 | STREPTOGRAMINES AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS | Aventis Pharma S.A. (FR) | 1997-05-02 | — | — | EP | disclosed |
| WO-1996004298-A1 | PURIFIED FORM OF STREPTOGRAMINES, PREPARATION OF SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | RHONE-POULENC RORER S.A. (FR) | 1996-02-15 | — | — | WO | disclosed |
| WO-1996001901-A1 | STREPTOGRAMINES AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS | RHONE-POULENC RORER S.A. (FR) | 1996-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020142947-A1 | STREPTOGRAMINS AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS | EMG1, FBL, SMS | HIF1A 1689/4885CYP3A4 2915/4885ALOX15 3530/4885 |
| US-20230391828-A1 | REGULATORS OF CELL DIVISION | PCNA, BOD1L1, MKI67 | HIF1A 1583/4885CYP3A4 4883/4885ALOX15 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.